GTHP.US Guided Therapeutics Inc
- Market cap
- USD 10.6M
- P/E
- -
- P/B
- 106.31x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is GTHP.US undervalued?
Graham numberThe Graham number of Guided Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guided Therapeutics Inc fundamental analysis
No fundamental analysis for Guided Therapeutics Inc yet.
Guided Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guided Therapeutics Inc
Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and change…
Full company profileGuided Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guided Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 244K | 57.0K | 36.0K | 102K | 81.0K | 13.0K | 98.0K | 7.00K | 767K | 0.00 |
| Gross Profit | -286K | -32.0K | -34.0K | 143K | 20.0K | -68.0K | 36.0K | 2.00K | 571K | 0.00 |
| Operating Income | -3.12M | -1.55M | -937K | -1.05M | -2.36M | -3.33M | -3.46M | -2.11M | -2.37M | -1.21M |
| EBITDA | -9.38M | 2.81M | -488K | 777K | -837K | -3.69M | -3.13M | -1.94M | -2.47M | -1.30M |
| Net Income | -10.7M | 1.02M | -1.92M | -279K | -2.07M | -4.34M | -3.49M | -2.42M | -3.20M | -2.00M |
| EPS | -173 | 0.38 | -0.58 | -0.02 | -0.15 | -0.09 | -0.06 | -0.04 | -0.04 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 489K | 236K | 1.18M | 1.35M | 2.04M | 3.37M | 1.67M | 1.38M | 1.32M | 1.60M |
| Total Liabilities | 19.9M | 16.1M | 18.1M | 12.2M | 7.49M | 6.25M | 5.48M | 6.27M | 7.33M | 6.78M |
| Shareholders' Equity | -19.4M | -15.8M | -16.9M | -10.9M | -5.45M | -2.88M | -3.81M | -4.89M | -6.01M | -5.18M |
| Cash & Short-term Investments | 1.00K | 0.00 | 899K | 182K | 643K | 2.31M | 591K | 388K | 63.0K | 369K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.14M | -1.37M | -806K | -1.88M | -1.59M | -1.48M | -1.75M | -1.12M | -1.07M | -2.47M |
| Capital Expenditure | 1.00K | 1.00K | 1.00K | 1.00K | 14.0K | 31.0K | 0.00 | 0.00 | 2.00K | 0.00 |
| Free Cash Flow | -1.14M | -1.37M | -806K | -1.88M | -1.61M | -1.51M | -1.75M | -1.12M | -1.07M | -2.47M |
| Ratios | ||||||||||
| ROA | -2,187.3% | 430.5% | -162.8% | -20.7% | -101.5% | -129.0% | -209.0% | -175.4% | -241.4% | -124.7% |
| Net Profit Margin | -4,383.6% | 1,782.5% | -5,336.1% | -273.5% | -2,555.6% | -33,392.3% | -3,560.2% | -34,528.6% | -416.7% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Guided Therapeutics Inc dividends
Guided Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:800 on Mar 29, 2019.
Who owns Guided Therapeutics Inc
- Insiders 38.23%
- Institutions 0.00%
- Public & others 61.77%
- Shares outstanding 96.5M
- Free float 59.6M
Guided Therapeutics Inc company profile
- Company name
- Guided Therapeutics Inc
- Ticker
- GTHP.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3
- Fiscal year end
- December
- Address
- 5835 Peachtree Corners East, Peachtree Corners, GA, United States, 30092
- Phone
- 770 242 8723
- Website
- guidedinc.com
About Guided Therapeutics Inc
Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.
Guided Therapeutics Inc management
1- Dr. Mark L. Faupel Ph.D.CEO, President, COO, Acting CFO, Secretary & Director · born 1955